RE: “USE OF A BAYESIAN APPROACH TO DECIDE WHEN TO STOP A THERAPEUTIC TRIAL: THE CASE OF A CHEMOPROPHYLAXIS TRIAL IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION”
As a methodological exercise, Kpozehuoen et al.'s Bayesian simulations are an important contribution in exploring the impact of different priors on reducing the size of a clinical acquired immunodeficiency syndrome trial. To compare the claimed efficiency gained by means of this Bayesian approa...
Gespeichert in:
| Veröffentlicht in: | American journal of epidemiology 2005-11, Vol.162 (10), p.1033-1035 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1035 |
|---|---|
| container_issue | 10 |
| container_start_page | 1033 |
| container_title | American journal of epidemiology |
| container_volume | 162 |
| creator | van Noord, Paulus A. H. van der Tweel, Ingeborg |
| description | As a methodological exercise, Kpozehuoen et al.'s Bayesian simulations are an important contribution in exploring the impact of different priors on reducing the size of a clinical acquired immunodeficiency syndrome trial. To compare the claimed efficiency gained by means of this Bayesian approach with an alternative method, van Nord et al. performed a sequential statistical analysis using the specifications given in the paper. |
| doi_str_mv | 10.1093/aje/kwi319 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68779467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>930598991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-1f61e11231e5fe663e8d77c1b0755f15e9d6140e6170662ec95dd02a5ef4b8373</originalsourceid><addsrcrecordid>eNqF0c1u0zAAB3ALgVgZXHgAZHHggBRmO7Gd7OalLrGUJiEfbOVipakjtWvXkbTauO1BQLzbngRXKSBx4WTZ_unvjz8ArzH6gFHgntUrc3Z9t3Rx8ASMsMeZwwhlT8EIIUScgDByAl70_QohjAOKnoMTzAjBPuIj8DOX5_Dx4XtVSJhOoIAXYiYLJRIosixPRRjBMoVjGaqxhJeRTA7TokwzS8tI5iKTValCWOZKxOeHJRiK31lhJKepTcmiWSyuVDEoqBIYVVN7hJpOqyQdy4kKlUzCGfys8qqw-xMZlipNHh9-vATP2nrdm1fH8RRUE1mGkROnH1UoYqdxPbRzcMuwwZi42NDWMOYaf8F5g-eIU9piaoIFwx4yDHPEGDFNQBcLRGpqWm_uu9w9Be-G3Ntu-3Vv-p3eLPvGrNf1jdnue818zgOP_R8SZD_X86mFb_-Bq-2-u7GP0MSlAbE9YYveD6jptn3fmVbfdstN3X3TGOlDudqWq4dyLX5zTNzPN2bxlx7btMAZwLLfmfs_-3V3re3NOdXR1RfNL-NxTj8FOnZ_AfLLo0A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>235924761</pqid></control><display><type>article</type><title>RE: “USE OF A BAYESIAN APPROACH TO DECIDE WHEN TO STOP A THERAPEUTIC TRIAL: THE CASE OF A CHEMOPROPHYLAXIS TRIAL IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION”</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>van Noord, Paulus A. H. ; van der Tweel, Ingeborg</creator><creatorcontrib>van Noord, Paulus A. H. ; van der Tweel, Ingeborg</creatorcontrib><description>As a methodological exercise, Kpozehuoen et al.'s Bayesian simulations are an important contribution in exploring the impact of different priors on reducing the size of a clinical acquired immunodeficiency syndrome trial. To compare the claimed efficiency gained by means of this Bayesian approach with an alternative method, van Nord et al. performed a sequential statistical analysis using the specifications given in the paper.</description><identifier>ISSN: 0002-9262</identifier><identifier>EISSN: 1476-6256</identifier><identifier>DOI: 10.1093/aje/kwi319</identifier><identifier>PMID: 16221807</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Anti-Infective Agents - therapeutic use ; Bayes Theorem ; Bayesian analysis ; Clinical trials ; Clinical Trials, Phase III as Topic - methods ; Endpoint Determination - methods ; Epidemiology ; HIV ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Humans ; Randomized Controlled Trials as Topic - methods ; Research Design</subject><ispartof>American journal of epidemiology, 2005-11, Vol.162 (10), p.1033-1035</ispartof><rights>Copyright Oxford University Press(England) Nov 15, 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c340t-1f61e11231e5fe663e8d77c1b0755f15e9d6140e6170662ec95dd02a5ef4b8373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16221807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Noord, Paulus A. H.</creatorcontrib><creatorcontrib>van der Tweel, Ingeborg</creatorcontrib><title>RE: “USE OF A BAYESIAN APPROACH TO DECIDE WHEN TO STOP A THERAPEUTIC TRIAL: THE CASE OF A CHEMOPROPHYLAXIS TRIAL IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION”</title><title>American journal of epidemiology</title><addtitle>Am. J. Epidemiol</addtitle><description>As a methodological exercise, Kpozehuoen et al.'s Bayesian simulations are an important contribution in exploring the impact of different priors on reducing the size of a clinical acquired immunodeficiency syndrome trial. To compare the claimed efficiency gained by means of this Bayesian approach with an alternative method, van Nord et al. performed a sequential statistical analysis using the specifications given in the paper.</description><subject>Anti-Infective Agents - therapeutic use</subject><subject>Bayes Theorem</subject><subject>Bayesian analysis</subject><subject>Clinical trials</subject><subject>Clinical Trials, Phase III as Topic - methods</subject><subject>Endpoint Determination - methods</subject><subject>Epidemiology</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Randomized Controlled Trials as Topic - methods</subject><subject>Research Design</subject><issn>0002-9262</issn><issn>1476-6256</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0c1u0zAAB3ALgVgZXHgAZHHggBRmO7Gd7OalLrGUJiEfbOVipakjtWvXkbTauO1BQLzbngRXKSBx4WTZ_unvjz8ArzH6gFHgntUrc3Z9t3Rx8ASMsMeZwwhlT8EIIUScgDByAl70_QohjAOKnoMTzAjBPuIj8DOX5_Dx4XtVSJhOoIAXYiYLJRIosixPRRjBMoVjGaqxhJeRTA7TokwzS8tI5iKTValCWOZKxOeHJRiK31lhJKepTcmiWSyuVDEoqBIYVVN7hJpOqyQdy4kKlUzCGfys8qqw-xMZlipNHh9-vATP2nrdm1fH8RRUE1mGkROnH1UoYqdxPbRzcMuwwZi42NDWMOYaf8F5g-eIU9piaoIFwx4yDHPEGDFNQBcLRGpqWm_uu9w9Be-G3Ntu-3Vv-p3eLPvGrNf1jdnue818zgOP_R8SZD_X86mFb_-Bq-2-u7GP0MSlAbE9YYveD6jptn3fmVbfdstN3X3TGOlDudqWq4dyLX5zTNzPN2bxlx7btMAZwLLfmfs_-3V3re3NOdXR1RfNL-NxTj8FOnZ_AfLLo0A</recordid><startdate>20051115</startdate><enddate>20051115</enddate><creator>van Noord, Paulus A. H.</creator><creator>van der Tweel, Ingeborg</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T2</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20051115</creationdate><title>RE: “USE OF A BAYESIAN APPROACH TO DECIDE WHEN TO STOP A THERAPEUTIC TRIAL: THE CASE OF A CHEMOPROPHYLAXIS TRIAL IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION”</title><author>van Noord, Paulus A. H. ; van der Tweel, Ingeborg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-1f61e11231e5fe663e8d77c1b0755f15e9d6140e6170662ec95dd02a5ef4b8373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Anti-Infective Agents - therapeutic use</topic><topic>Bayes Theorem</topic><topic>Bayesian analysis</topic><topic>Clinical trials</topic><topic>Clinical Trials, Phase III as Topic - methods</topic><topic>Endpoint Determination - methods</topic><topic>Epidemiology</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Randomized Controlled Trials as Topic - methods</topic><topic>Research Design</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Noord, Paulus A. H.</creatorcontrib><creatorcontrib>van der Tweel, Ingeborg</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Noord, Paulus A. H.</au><au>van der Tweel, Ingeborg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RE: “USE OF A BAYESIAN APPROACH TO DECIDE WHEN TO STOP A THERAPEUTIC TRIAL: THE CASE OF A CHEMOPROPHYLAXIS TRIAL IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION”</atitle><jtitle>American journal of epidemiology</jtitle><addtitle>Am. J. Epidemiol</addtitle><date>2005-11-15</date><risdate>2005</risdate><volume>162</volume><issue>10</issue><spage>1033</spage><epage>1035</epage><pages>1033-1035</pages><issn>0002-9262</issn><eissn>1476-6256</eissn><abstract>As a methodological exercise, Kpozehuoen et al.'s Bayesian simulations are an important contribution in exploring the impact of different priors on reducing the size of a clinical acquired immunodeficiency syndrome trial. To compare the claimed efficiency gained by means of this Bayesian approach with an alternative method, van Nord et al. performed a sequential statistical analysis using the specifications given in the paper.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>16221807</pmid><doi>10.1093/aje/kwi319</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9262 |
| ispartof | American journal of epidemiology, 2005-11, Vol.162 (10), p.1033-1035 |
| issn | 0002-9262 1476-6256 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68779467 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Anti-Infective Agents - therapeutic use Bayes Theorem Bayesian analysis Clinical trials Clinical Trials, Phase III as Topic - methods Endpoint Determination - methods Epidemiology HIV HIV Infections - drug therapy Human immunodeficiency virus Humans Randomized Controlled Trials as Topic - methods Research Design |
| title | RE: “USE OF A BAYESIAN APPROACH TO DECIDE WHEN TO STOP A THERAPEUTIC TRIAL: THE CASE OF A CHEMOPROPHYLAXIS TRIAL IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION” |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T23%3A08%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RE:%20%E2%80%9CUSE%20OF%20A%20BAYESIAN%20APPROACH%20TO%20DECIDE%20WHEN%20TO%20STOP%20A%20THERAPEUTIC%20TRIAL:%20THE%20CASE%20OF%20A%20CHEMOPROPHYLAXIS%20TRIAL%20IN%20HUMAN%20IMMUNODEFICIENCY%20VIRUS%20INFECTION%E2%80%9D&rft.jtitle=American%20journal%20of%20epidemiology&rft.au=van%20Noord,%20Paulus%20A.%20H.&rft.date=2005-11-15&rft.volume=162&rft.issue=10&rft.spage=1033&rft.epage=1035&rft.pages=1033-1035&rft.issn=0002-9262&rft.eissn=1476-6256&rft_id=info:doi/10.1093/aje/kwi319&rft_dat=%3Cproquest_cross%3E930598991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=235924761&rft_id=info:pmid/16221807&rfr_iscdi=true |